 |
471 Diseases |  |
207 Trials |
|
207 Trials |  |
10577 News |  |
| «12...103104105106107108109110111112113...132133» |
- ||| New trial, Real-world evidence, Real-world, Metastases: Treat ER+ight: Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy (clinicaltrials.gov) - Apr 28, 2016
P=N/A, N=320, Recruiting, Sponsor: Novartis Pharmaceuticals
- |||| cyclosporin A microemulsion / Generic mfg., everolimus / Generic mfg., mycophenolate sodium / Generic mfg.
Trial primary completion date: Comparison of Efficacy and Safety of Treatment With a Calcineurin Inhibitor (CNI)Versus a CNI-free Treatment in Renal Transplantation (CIME) (clinicaltrials.gov) - Apr 26, 2016
P3, N=134, Recruiting, Sponsor: Centre Hospitalier Universitaire, Amiens
Trial primary completion date: Jul 2015 --> May 2017
- everolimus / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Everolimus in Treating Cutaneous T-cell Lymphoma (clinicaltrials.gov) - Apr 26, 2016
P2, N=1, Terminated, Sponsor: Adam Lerner
Trial primary completion date: Jul 2015 --> May 2017 N=39 --> 1 | Recruiting --> Terminated | Trial primary completion date: Apr 2016 --> May 2015; Poor enrollment
- Signifor (pasireotide) / Recordati
Trial completion, Trial primary completion date, Combination therapy: SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer (clinicaltrials.gov) - Apr 25, 2016
P2, N=19, Completed, Sponsor: Federico II University
N=39 --> 1 | Recruiting --> Terminated | Trial primary completion date: Apr 2016 --> May 2015; Poor enrollment Recruiting --> Completed | Trial primary completion date: May 2012 --> Mar 2016
- Farydak (panobinostat) / Secura Bio
Trial primary completion date, Combination therapy, Epigenetic controller: Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma (clinicaltrials.gov) - Apr 22, 2016
P1/2, N=148, Active, not recruiting, Sponsor: Mayo Clinic
Recruiting --> Completed | Trial primary completion date: May 2012 --> Mar 2016 Trial primary completion date: Jan 2016 --> Jan 2017
- | everolimus / Generic mfg.
Trial completion, Trial initiation date, Trial primary completion date: Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC) (clinicaltrials.gov) - Apr 22, 2016
P1/2, N=20, Completed, Sponsor: Children's Hospital Medical Center, Cincinnati
Trial primary completion date: Jan 2016 --> Jan 2017 Active, not recruiting --> Completed | Initiation date: Mar 2015 --> Jan 2010 | Trial primary completion date: Mar 2019 --> Apr 2016
- ||||||| everolimus / Generic mfg.
Trial completion: NEVERWOUND: Everolimus in de Novo Kidney Transplant Recipients (clinicaltrials.gov) - Apr 21, 2016
P3, N=383, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | Initiation date: Mar 2015 --> Jan 2010 | Trial primary completion date: Mar 2019 --> Apr 2016 Active, not recruiting --> Completed
- Signifor LAR (pasireotide long acting release) / Recordati
Trial primary completion date, Combination therapy, Metastases: Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs (clinicaltrials.gov) - Apr 21, 2016
P1, N=17, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Trial primary completion date: Apr 2016 --> Oct 2017
- everolimus / Generic mfg.
Trial primary completion date: A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous Sclerosis (clinicaltrials.gov) - Apr 20, 2016
P2, N=48, Recruiting, Sponsor: Cardiff University
Trial primary completion date: Apr 2016 --> Oct 2017 Trial primary completion date: Jul 2016 --> Oct 2016
- Farydak (panobinostat) / Secura Bio, Sutent (sunitinib) / Pfizer
Trial primary completion date, Combination therapy, Metastases: Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate (clinicaltrials.gov) - Apr 19, 2016
P1/2, N=26, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Jul 2016 --> Oct 2016 Trial primary completion date: Jun 2017 --> Oct 2015
- ganitumab (AMG 479) / Takeda, ImmunityBio
Trial primary completion date, Combination therapy, Metastases: Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors (clinicaltrials.gov) - Apr 19, 2016
P1, N=30, Active, not recruiting, Sponsor: Shadia Jalal
Trial primary completion date: Jun 2017 --> Oct 2015 Trial primary completion date: Jun 2015 --> Feb 2014
- letrozole / Generic mfg., everolimus / Generic mfg.
New P2 trial: A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer (clinicaltrials.gov) - Apr 18, 2016
P2, N=40, Not yet recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- everolimus / Generic mfg., sorafenib / Generic mfg.
Trial completion, Combination therapy, Metastases: SAKK 77/08: Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer (clinicaltrials.gov) - Apr 15, 2016
P2, N=106, Completed, Sponsor: Swiss Group for Clinical Cancer Research
Trial primary completion date: Jun 2015 --> Feb 2014 Active, not recruiting --> Completed
- || everolimus / Generic mfg.
Trial primary completion date, Combination therapy: Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score (clinicaltrials.gov) - Apr 15, 2016
P2, N=66, Recruiting, Sponsor: Yale University
Active, not recruiting --> Completed Trial primary completion date: Jan 2017 --> Jan 2018
- | everolimus / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date: Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer (clinicaltrials.gov) - Apr 14, 2016
P2, N=42, Active, not recruiting, Sponsor: Emory University
Trial primary completion date: Jan 2017 --> Jan 2018 Recruiting --> Active, not recruiting | N=90 --> 42 | Trial primary completion date: Oct 2016 --> Apr 2017
- Signifor (pasireotide) / Recordati
Trial primary completion date, Combination therapy, Metastases: Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors (clinicaltrials.gov) - Apr 14, 2016
P1, N=32, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting | N=90 --> 42 | Trial primary completion date: Oct 2016 --> Apr 2017 Trial primary completion date: Apr 2014 --> Apr 2016
- temozolomide / Generic mfg., everolimus / Generic mfg.
Trial primary completion date, Combination therapy, Metastases: RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors (clinicaltrials.gov) - Apr 14, 2016
P1/2, N=12, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Apr 2014 --> Apr 2016 Trial primary completion date: Sep 2014 --> Jul 2016
- everolimus / Generic mfg.
Biomarker, New trial, Monotherapy, IO biomarker: Biomarkers Predicting Successful Tacrolimus Withdrawal and Everolimus (Zortress) Monotherapy Early After Liver Transplantation (clinicaltrials.gov) - Apr 13, 2016
P=N/A, N=40, Recruiting, Sponsor: Northwestern University
- | Kisqali (ribociclib) / Novartis
New P1/2 trial, Combination therapy, Metastases: TRINITI-1: Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor. (clinicaltrials.gov) - Apr 8, 2016
P1/2, N=40, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- | dactolisib (RTB101) / Adicet Bio
Trial termination, Metastases: Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors (clinicaltrials.gov) - Apr 8, 2016
P2, N=62, Terminated, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Sep 2014 --> Jul 2016 Completed --> Terminated; This trial was terminated based on an interim analysis as BEZ235 did not demonstrate a progression free survival advantage to everolimus treatment.
- || Xofigo (radium Ra-223 dichloride) / Bayer
Trial primary completion date, Combination therapy, Metastases: Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer (clinicaltrials.gov) - Apr 7, 2016
P2, N=311, Recruiting, Sponsor: Bayer
Completed --> Terminated; This trial was terminated based on an interim analysis as BEZ235 did not demonstrate a progression free survival advantage to everolimus treatment. Trial primary completion date: Sep 2018 --> Jun 2019
- letrozole / Generic mfg., everolimus / Generic mfg.
Trial suspension: Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer (clinicaltrials.gov) - Apr 4, 2016
P2, N=20, Suspended, Sponsor: Mayo Clinic
Trial primary completion date: Sep 2018 --> Jun 2019 Active, not recruiting --> Suspended
- || letrozole / Generic mfg., everolimus / Generic mfg.
Trial primary completion date, Combination therapy, Metastases: Bolero-4: Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Apr 1, 2016
P2, N=202, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Suspended Trial primary completion date: Dec 2016 --> Jun 2016
- everolimus / Generic mfg., sorafenib / Generic mfg.
Trial primary completion date: Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer (clinicaltrials.gov) - Mar 31, 2016
P2, N=41, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Dec 2016 --> Jun 2016 Trial primary completion date: Jun 2016 --> Jun 2017
- | cisplatin / Generic mfg., everolimus / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date, Metastases: Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies (clinicaltrials.gov) - Mar 31, 2016
P1, N=12, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Jun 2016 --> Jun 2017 Active, not recruiting --> Completed | N=30 --> 12 | Trial primary completion date: Aug 2016 --> Mar 2016
- everolimus / Generic mfg.
Trial primary completion date: A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD (clinicaltrials.gov) - Mar 31, 2016
P2, N=30, Recruiting, Sponsor: New York University School of Medicine
Active, not recruiting --> Completed | N=30 --> 12 | Trial primary completion date: Aug 2016 --> Mar 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- ||||| serabelisib (MLN1117) / Takeda
New P2 trial, Metastases: MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma (clinicaltrials.gov) - Mar 31, 2016
P2, N=189, Not yet recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
- ||||| everolimus / Generic mfg., cyclosporine / Generic mfg.
Enrollment closed, Combination therapy: Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients. (clinicaltrials.gov) - Mar 28, 2016
P3, N=75, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2015 --> Dec 2016 Recruiting --> Active, not recruiting
- || Votrient (pazopanib) / Novartis, BeiGene
Trial primary completion date, Metastases: Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients (clinicaltrials.gov) - Mar 25, 2016
P1, N=62, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Trial primary completion date: Oct 2016 --> Oct 2017
- | lapatinib / Generic mfg., everolimus / Generic mfg.
Enrollment open, Trial primary completion date, Metastases: Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer (clinicaltrials.gov) - Mar 25, 2016
P2, N=45, Recruiting, Sponsor: University of Kansas Medical Center
Trial primary completion date: Oct 2016 --> Oct 2017 Active, not recruiting --> Recruiting | Trial primary completion date: Nov 2015 --> May 2016
- |||| Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment open, Enrollment change, Combination therapy, Metastases: Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors (clinicaltrials.gov) - Mar 25, 2016
P1/2, N=261, Recruiting, Sponsor: Pharmacyclics
Active, not recruiting --> Recruiting | Trial primary completion date: Nov 2015 --> May 2016 Active, not recruiting --> Recruiting | N=189 --> 261
- ||||||| Trial completion, Enrollment change: Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen (clinicaltrials.gov) - Mar 25, 2016
P3, N=756, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Recruiting | N=189 --> 261 Active, not recruiting --> Completed | N=450 --> 756
- ||| Enrollment closed, Trial primary completion date, Combination therapy: 12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients (clinicaltrials.gov) - Mar 24, 2016
P4, N=617, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | N=450 --> 756 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2017 --> Mar 2016
- | everolimus / Generic mfg.
Enrollment change, Metastases: Phase II Study of Everolimus Beyond Progression (clinicaltrials.gov) - Mar 24, 2016
P2, N=38, Recruiting, Sponsor: Emory University
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2017 --> Mar 2016 N=70 --> 38
- cisplatin / Generic mfg., everolimus / Generic mfg., gemcitabine / Generic mfg.
Enrollment closed, Metastases: Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast Cancer (clinicaltrials.gov) - Mar 23, 2016
P2, N=116, Active, not recruiting, Sponsor: National Cancer Center, Korea
N=70 --> 38 Recruiting --> Active, not recruiting
- || everolimus / Generic mfg.
Trial primary completion date, Metastases: Treatment of Patients With RAD001 With Progressive Sarcoma (clinicaltrials.gov) - Mar 22, 2016
P2, N=71, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2015 --> Dec 2016
- SNX-5422 / Esanex
Trial primary completion date: Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors (clinicaltrials.gov) - Mar 22, 2016
P1, N=15, Recruiting, Sponsor: Esanex Inc.
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: May 2016 --> Aug 2016
- ||| everolimus / Generic mfg., vinorelbine tartrate / Generic mfg.
Enrollment closed, Trial primary completion date, Combination therapy, Monotherapy, Metastases: VicTORia: Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer (clinicaltrials.gov) - Mar 21, 2016
P2, N=139, Active, not recruiting, Sponsor: AIO-Studien-gGmbH
Trial primary completion date: May 2016 --> Aug 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2016 --> Dec 2016
- | Enrollment closed, Enrollment change: Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer (clinicaltrials.gov) - Mar 21, 2016
P1/2, N=17, Active, not recruiting, Sponsor: Emory University
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2016 --> Dec 2016 Recruiting --> Active, not recruiting | N=63 --> 17
- | everolimus / Generic mfg.
Enrollment closed, Combination therapy, Metastases: Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer (clinicaltrials.gov) - Mar 21, 2016
P2, N=48, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
Recruiting --> Active, not recruiting | N=63 --> 17 Recruiting --> Active, not recruiting
- || Votrient (pazopanib) / Novartis, BeiGene
Trial primary completion date, Metastases: CATChEz: Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Mar 18, 2016
P2, N=70, Recruiting, Sponsor: Novartis
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2016 --> Apr 2016
- Votrient (pazopanib) / Novartis, BeiGene
Enrollment change, Trial primary completion date, Metastases: Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer (clinicaltrials.gov) - Mar 18, 2016
P1, N=34, Recruiting, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Jan 2016 --> Apr 2016 N=44 --> 34 | Trial primary completion date: Dec 2015 --> Dec 2016
- Xtandi (enzalutamide capsule) / Pfizer, Astellas
Enrollment closed, Metastases: Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer (clinicaltrials.gov) - Mar 18, 2016
P1, N=38, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
N=44 --> 34 | Trial primary completion date: Dec 2015 --> Dec 2016 Recruiting --> Active, not recruiting
- lenalidomide / Generic mfg., everolimus / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy, Metastases: Study of Everolimus (RAD001) in Combination With Lenalidomide (clinicaltrials.gov) - Mar 18, 2016
P1, N=44, Active, not recruiting, Sponsor: Emory University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=58 --> 44 | Trial primary completion date: Dec 2016 --> Mar 2017
- polyTregs / National Institute of Allergy and Infectious Diseases
New P1/2 trial, IO biomarker: TASK: Treg Therapy in Subclinical Inflammation in Kidney Transplantation (clinicaltrials.gov) - Mar 18, 2016
P1/2, N=45, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- vatalanib (PTK787) / Novartis, Bayer
Trial primary completion date, Combination therapy, Metastases: Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 16, 2016
P1, N=96, Active, not recruiting, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting | N=58 --> 44 | Trial primary completion date: Dec 2016 --> Mar 2017 Trial primary completion date: Dec 2015 --> Dec 2016
- Rituxan (rituximab) / Roche
Trial completion: The Combination of Rad001 and Rituximab In Patients With Non-hodgkin's Lymphomas (clinicaltrials.gov) - Mar 15, 2016
P1/2, N=21, Completed, Sponsor: The Lymphoma Academic Research Organisation
Trial primary completion date: Dec 2015 --> Dec 2016 Active, not recruiting --> Completed
- | Herceptin (trastuzumab) / Roche
Trial completion, Combination therapy, Metastases: Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Mar 10, 2016
P1/2, N=11, Completed, Sponsor: Beth Israel Deaconess Medical Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Trial primary completion date, Combination therapy, Metastases: BOLERO-6: A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. (clinicaltrials.gov) - Mar 8, 2016
P2, N=317, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Trial primary completion date: Jul 2016 --> Nov 2016
- everolimus / Generic mfg.
Trial primary completion date: NFC-RAD001: Everolimus for Children With NF1 Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas (clinicaltrials.gov) - Mar 8, 2016
P2, N=23, Active, not recruiting, Sponsor: University of Alabama at Birmingham
Trial primary completion date: Jul 2016 --> Nov 2016 Trial primary completion date: Feb 2016 --> Sep 2016